Compare Danaher Corporation (DHR) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Oklo Inc — how do they compare? Danaher Corporation trades at $220.03 (market cap $152.87B), while Oklo Inc trades at $34.68 (market cap $6.43B). The key difference: Danaher Corporation is far larger — about 23.8× Oklo Inc's market cap, and Danaher Corporation pays a 0.74% dividend while Oklo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Oklo Inc for 32 Days on average.
| DHR | OKLO | |
|---|---|---|
Market Cap | $152.87B | $6.43B |
Volume | 5,228,698 | 16,238,368 |
Sector | Health | Utilities |
52-Week High | $242.05 | $174.14 |
52-Week Low | $161.91 | $34.57 |
Typical Hold Time | 69 Days | 32 Days |
Enterprise Value | $175.08B | $3.97B |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
OKLO trades at $34.65, down 5.91% today, with a bearish technical signal from moving averages. The company shows no revenue in 2025 and negative net income of -$105.66M, with profitability metrics deeply negative. Analyst consensus remains strongly bullish with a $78.63 price target, but recent news highlights competitive pressures and dilution concerns from stock sales.
The outlook hinges on OKLO's ability to commercialize its nuclear reactor pipeline. High institutional buy ratings suggest long-term potential, but execution risks, cash burn, and intense competition in the SMR space pose significant challenges. The stock offers speculative growth exposure amid substantial operational and financial headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
